Navigation Links
Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:5/19/2011

SAN DIEGO, May 19, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data from a completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY 86-9766 in advanced cancer patients will be presented in an Oral Abstract Session at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Sunday, June 5, 2011.

Presentation details are as follows:Presentation Title:

Safety, Pharmacokinetics, and Pharmacodynamics Results From a Phase 1 Trial of BAY 86-9766 (RDEA119), a MEK Inhibitor, In Patients with Advanced Cancer Session Type/Title:

Oral Abstract Session: Developmental Therapeutics – Experimental Therapeutics Author/Presenter:

Colin Weekes, MD, PhD – Assistant Professor, Division of Medical Oncology, University of Colorado School of MedicineAbstract ID:

3007Date/Time:

Sunday, June 5, 2011 from 9:30 AM – 12:30 PM CDTAbout BAY 86-9766BAY 86-9766 (RDEA119) is a potent and highly selective inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer Healthcare (Bayer). Preclinical and clinical data suggest that BAY 86-9766 has favorable properties, including once-daily oral dosing and excellent selectivity. In addition, BAY 86-9766 has been shown to suppress tumor cell growth in vitro and in vivo. Preclinical in vitro and in vivo oncology studies of BAY 86-9766 have demonstrated significant potential synergy across multiple tumor types when used in combination with other anti-cancer agents, including sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals, Inc.).

About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)


'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
2. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
3. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Ardea Biosciences to Present at Two Upcoming Investor Conferences
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
10. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):